The $242.65 million is the most raised in a local life sciences IPO since Passage Bio went public in March 2020.

The company is the fourth local life sciences company to complete an initial public stock offering in 2021.

A flurry of biotechs are expected to hit Nasdaq this week, with two companies, Ambrx Biopharma and Century Therapeutics, setting the terms for their public debuts, with expected raises at $126 million and $200 million, respectively.

Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.

Century Therapeutics Inc. raised $160 million in a series C round to progress its preclinical pipeline of allogeneic cell therapies for cancer, which are derived from induced pluripotent stem cells (iPSCs), and to expand its operational, laboratory and production facilities across several locations.

It’s been a busy few years for Pennsylvania-based Century Therapeutics since it burst onto the scene with a $250M funding haul in summer 2019. Now, the biotech is scaling up its manufacturing capacity as part of a companywide footprint buildout.

Century Therapeutics was created by the investment firm Versant Ventures and has secured $250 million in total initial funding. The firm has partnered with Fujifilm Cellular Dynamics (FCDI) to license the induced pluripotent stem cells (iPSC) immune effector cell platform that will underlie Century’s investigational oncology therapies.

Century Therapeutics is the latest start-up to launch with plans to develop off-the-shelf cancer cell therapies, and it has gene editing tools, stem cell technology, and $250 million in financing to do it.

With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.

The financing, which was announced Monday, comes via the German pharma's venture investment arm Leaps by Bayer. Versant Ventures, Century's creator, and Fujifilm Cellular Dynamics will add another $35 million to bring Century's funding to $250 million.

Versant Ventures’ Century Therapeutics has exited stealth with $250 million to take allogeneic cell therapies into the clinic. Bayer’s VC wing led the investment with the support of Versant and Fujifilm Cellular Dynamics (FCDI).

Company is developing cellular therapy treatments for cancer. Corporate and venture-capital investors are funneling $250 million into startup Century Therapeutics LLC to finance an effort to cure cancers through a new type of cellular therapy.

Look out Fate Therapeutics — Versant Ventures’ Century Therapeutics is lurking in the burgeoning field of off-the-shelf cell therapeutics that offer the promise of quicker, cheaper and potent cancer treatments. The Philadelphia-based biotech unveiled on Monday a meaty $250 million round of financing — led by Bayer’s venture arm — after Versant spawned it in 2018 to develop induced pluripotent stem cells (iPSC)-derived products to fight cancer.

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding.